Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Gestational choriocarcinoma is a gestational trophoblastic tumor (GTT) occurring secondary to pregnancy (ectopic or normal), miscarriage, voluntary termination of pregnancy (VTP) or a hydatidiform mole.
Features include always present findings: Choriocarcinoma; and very common findings: Neoplasm, Trophoblastic tumor, and Metrorrhagia.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Neoplasm | 1 | Neoplasm |
Biomarker and diagnostic research for gestational choriocarcinoma has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 3 very common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for gestational choriocarcinoma.
179 publications have been identified in PubMed for gestational choriocarcinoma. Research spans Case Report / Case Series (40%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 72 | 40% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:30 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
45 |
25% |
Laboratory research | 26 | 15% |
Disease patterns and progression | 12 | 7% |
Testing and diagnosis research | 10 | 6% |
Clinical study results | 5 | 3% |
New treatment approaches | 5 | 3% |
Other research | 4 | 2% |
Pfister K (2026). [PMID: 41810059](https://pubmed.ncbi.nlm.nih.gov/41810059/). *Case reports in obstetrics and gynecology*. [Case Report / Case Series]
Sun H (2026). [PMID: 41939752](https://pubmed.ncbi.nlm.nih.gov/41939752/). *Front Med (Lausanne)*. [Review / Meta-Analysis]
Wang T (2026). [PMID: 41808328](https://pubmed.ncbi.nlm.nih.gov/41808328/). *Ann Med*. [Review / Meta-Analysis]
Zoly RN (2026). [PMID: 41768783](https://pubmed.ncbi.nlm.nih.gov/41768783/). *Case reports in obstetrics and gynecology*. [Gene Therapy / Novel Therapeutics]
Lin LH (2026). [PMID: 40644332](https://pubmed.ncbi.nlm.nih.gov/40644332/). *Int J Gynecol Pathol*. [Diagnostic / Biomarker]
AlJulaih GH (2026). [PMID: 32965896](https://pubmed.ncbi.nlm.nih.gov/32965896/). *Unknown Journal*. [Case Report / Case Series]
Filfilan NNA (2026). [PMID: 42047768](https://pubmed.ncbi.nlm.nih.gov/42047768/). *Naunyn Schmiedebergs Arch Pharmacol*. [Review / Meta-Analysis]
Xiao Y (2026). [PMID: 42052480](https://pubmed.ncbi.nlm.nih.gov/42052480/). *Front Oncol*. [Case Report / Case Series]
Al-Hajeili M (2026). [PMID: 42118332](https://pubmed.ncbi.nlm.nih.gov/42118332/). *Cancer Chemother Pharmacol*. [Review / Meta-Analysis]
Alshaikh ABA (2026). [PMID: 41770291](https://pubmed.ncbi.nlm.nih.gov/41770291/). *Clin Exp Metastasis*. [Review / Meta-Analysis]
AI-curated news mentioning gestational choriocarcinoma
Updated May 12, 2026
New research explores the GSK-3β/mTOR axis as a potential target to overcome chemoresistance in gestational choriocarcinoma. This study highlights molecular mechanisms and therapeutic opportunities that could enhance treatment efficacy.